Literature DB >> 12100033

Impaired up-regulation of CD70 and CD86 in naive (CD27-) B cells from patients with common variable immunodeficiency (CVID).

C Groth1, R Drager, K Warnatz, G Wolff-Vorbeck, S Schmidt, H Eibel, M Schlesier, H-H Peter.   

Abstract

CVID is characterized by reduced serum levels of all switched immunoglobulin isotypes (IgG, IgA, IgE) predisposing patients to recurrent infections of their respiratory and gastrointestinal tract. Correspondingly, most CVID patients exhibit a severely decreased proportion of class switched memory B cells (CD19+CD27+IgD-IgM-IgG+ or IgA+) in their peripheral blood (CVID type I). We previously identified a subgroup of CVID patients showing a significantly reduced expression of CD86 and CD137 following activation in vitro of PBMC or purified B cells (CD19+) with anti-IgM plus IL-2. Here we extend our previous studies by asking whether highly purified, cell-sorted naive B cells show already an expression defect of B cell surface molecules relevant in activation (CD39, CD69), differentiation (CD24, CD27, CD38) or T-B interaction (CD25, CD70, CD86). We stimulated cell-sorted, naive B cells (CD19+CD27-IgM+IgDhighIgG-IgA-) from 10 CVID patients and 10 healthy controls for 4 days with anti-IgM plus IL-2 in the absence or presence of autologous CD4+ T cells and measured the expression of the referred surface molecules. Based on reduced or normal numbers of switched memory B cells the CVID patients had previously been classified into eight type I patients and two type II patients, respectively. Interestingly, only the molecules CD25, CD70 and CD86, all relevant in cognate T-B interaction, showed a significantly lower expression in naive B cells from CVID patients compared to controls. While coculture with autologous CD4+ T cells normalized the CD25 expression, CD70 and CD86 expression remained subnormal, notably in the eight CVID patients of type I. These findings strongly suggest an intrinsic signalling or expression defect for CD70/CD86 at the level of naive B cells in type I CVID patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100033      PMCID: PMC1906432          DOI: 10.1046/j.1365-2249.2002.01883.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  44 in total

1.  Activated B cells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin.

Authors:  S Nonoyama; M Farrington; H Ishida; M Howard; H D Ochs
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

2.  Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency.

Authors:  M C Sneller; W Strober
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

3.  Defective DNA synthesis by T cells in acquired 'common-variable' hypogammaglobulinaemia on stimulation with mitogens.

Authors:  M E North; G P Spickett; J Allsop; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

4.  Possible role of IL-2 deficiency for hypogammaglobulinaemia in patients with common variable immunodeficiency.

Authors:  J A Rump; A Jahreis; M Schlesier; R Dräger; I Melchers; H H Peter
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

5.  Classification of patients with common variable immunodeficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2.

Authors:  A Bryant; N C Calver; E Toubi; A D Webster; J Farrant
Journal:  Clin Immunol Immunopathol       Date:  1990-08

6.  Polyclonal immunoglobulin secretion in patients with common variable immunodeficiency using monoclonal B cell differentiation factors.

Authors:  L Mayer; S M Fu; C Cunningham-Rundles; H G Kunkel
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

7.  CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency.

Authors:  M Farrington; L S Grosmaire; S Nonoyama; S H Fischer; D Hollenbaugh; J A Ledbetter; R J Noelle; A Aruffo; H D Ochs
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

8.  Defects in proliferative responses of T cells from patients with common variable immunodeficiency on direct activation of protein kinase C.

Authors:  M E North; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

Review 9.  The CD40 antigen and its ligand.

Authors:  J Banchereau; F Bazan; D Blanchard; F Brière; J P Galizzi; C van Kooten; Y J Liu; F Rousset; S Saeland
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 10.  T-cell abnormalities in common variable immunodeficiency.

Authors:  J S Jaffe; E Eisenstein; M C Sneller; W Strober
Journal:  Pediatr Res       Date:  1993-01       Impact factor: 3.756

View more
  12 in total

1.  Role of B cells in common variable immune deficiency.

Authors:  Sam Ahn; Charlotte Cunningham-Rundles
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

2.  Ill-defined germinal centers and severely reduced plasma cells are histological hallmarks of lymphadenopathy in patients with common variable immunodeficiency.

Authors:  Susanne Unger; Maximilian Seidl; Annette Schmitt-Graeff; Joachim Böhm; Klaudia Schrenk; Claudia Wehr; Sigune Goldacker; Ruth Dräger; Barbara C Gärtner; Paul Fisch; Martin Werner; Klaus Warnatz
Journal:  J Clin Immunol       Date:  2014-05-02       Impact factor: 8.317

Review 3.  Common Variable Immunodeficiency and Liver Involvement.

Authors:  Junmin Song; Ana Lleo; Guo Xiang Yang; Weici Zhang; Christopher L Bowlus; M Eric Gershwin; Patrick S C Leung
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

4.  Deficiency of somatic hypermutation of immunoglobulin G transcripts is a better predictor of severe respiratory tract infections than lack of memory B cells in common variable immunodeficiency.

Authors:  Lone Schejbel; Hanne Marquart; Vagn Andersen; Henrik Permin; Pernille Andersen; Arne Svejgaard; Torben Barington
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

5.  Defective maturation of dendritic cells in common variable immunodeficiency.

Authors:  T H Scott-Taylor; M R Green; M Raeiszadeh; S Workman; A D Webster
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

6.  Adult survivors of invasive pneumococcal disease exhibit defective B cell function.

Authors:  Tom C Darton; James B Wing; Andrew Lees; Andrew W Heath; Robert C Read
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

7.  B Cell-Intrinsic Expression of the HuR RNA-Binding Protein Is Required for the T Cell-Dependent Immune Response In Vivo.

Authors:  Amy DeMicco; Martin S Naradikian; Vishal J Sindhava; Je-Hyun Yoon; Myriam Gorospe; Gerald B Wertheim; Michael P Cancro; Craig H Bassing
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

8.  Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects.

Authors:  B Piqueras; C Lavenu-Bombled; L Galicier; F Bergeron-van der Cruyssen; L Mouthon; S Chevret; P Debré; C Schmitt; E Oksenhendler
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

9.  High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID).

Authors:  Barry R Zeeberg; Haiying Qin; Sudarshan Narasimhan; Margot Sunshine; Hong Cao; David W Kane; Mark Reimers; Robert M Stephens; David Bryant; Stanley K Burt; Eldad Elnekave; Danielle M Hari; Thomas A Wynn; Charlotte Cunningham-Rundles; Donn M Stewart; David Nelson; John N Weinstein
Journal:  BMC Bioinformatics       Date:  2005-07-05       Impact factor: 3.169

10.  Defective Bcl-2 expression in memory B cells from common variable immunodeficiency patients.

Authors:  L Del Pino Molina; J M Torres Canizales; O Pernía; R Rodríguez Pena; I Ibanez de Caceres; E López Granados
Journal:  Clin Exp Immunol       Date:  2020-10-08       Impact factor: 5.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.